Back grey_arrow_rt.gif
 
 
Boehringer Ingelheim Licenses HCV Drugs
 
 
  BIOTA HOLDINGS SIGNS $US102MLN LICENSING DEAL
 
Asia Pulse Businesswire - Nov. 27, 2006
 
SYDNEY, Nov 27 Asia Pulse - Biota Holdings Ltd has signed a $US102 million ($A132.12 million) global licensing deal with German pharmaceutical giant Boehringer Ingelheim to develop and commercialise a potential treatment for Hepatitis C Virus (HCV).
 
Biota said today it had entered a worldwide research collaboration and licensing agreement with Boehringer for its novel nucleoside analogues that are designed to treat HCV and possibly other diseases.
 
Under the deal, Biota is eligible to receive payments of up to $102 million if its products achieve certain clinical, regulatory and commercialisation milestones.
 
That includes an initial technology access fee and research support.
 
It will also receive royalties on future sales of licensed products marketed by Boehringer, a company operating in 47 countries, though terms of the agreement were not disclosed.
 
Biota, which is Melbourne-based, will be responsible for the drug discovery research, and Boehringer, the worldwide development of potential compounds and their commercialisation.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org